Guggenheim lowered the firm’s price target on Xilio Therapeutics to $6 from $9 and keeps a Buy rating on the shares after the company reported initial Ph. I/II monotherapy data for XTX202 at SITC and hosted an investor event to discuss the data and pipeline updates. Initial clinical data for XTX202 showed clean safety, but the firm notes that the data are below investor expectations of about 10%-15% ORR in IO-sensitive tumor types at the target dose range. The firm has updated its model with lower odds of success for XTX202 and updated estimates for XTX101 in MSS CRC.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on XLO:
- Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors
- Xilio reports initial monotherapy safety and anti-tumor activity data for XTX202
- Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting
- Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
